Compare Organon & Co. Common Stock (OGN) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Orion Office REIT Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Orion Office REIT Inc trades at $2.11 (market cap $119.79M). The key difference: Organon & Co. Common Stock is far larger — about 30.1× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays the higher dividend (3.81%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Orion Office REIT Inc for 34 Days on average.
| OGN | ONL | |
|---|---|---|
Market Cap | $3.61B | $119.79M |
Volume | 1,808,049 | 347,277 |
Sector | Health | Real Estate |
52-Week High | $13.81 | $3.00 |
52-Week Low | $5.70 | $1.93 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $11.03B | $536.73M |
Dividend Yield | 0.58% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
ONL trades at $2.10, down 2.33% on the day, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported Q2 2026 EPS of $0.42, beating expectations, but maintains negative net income margins and declining revenue trends from $208M in 2022 to $148M in 2025. Analyst consensus is split evenly between Buy and Hold ratings, with no Sell recommendations.
The outlook remains challenging with persistent net losses and high debt levels, though the deep discount to book value (P/B 0.19) offers potential upside if operational improvements materialize. Key risks include ongoing revenue contraction, negative profitability, and significant leverage exposure in the office REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
